Healthineers Projects 4%-5% Growth as China Weighs
Medical technology buyers and diagnostics suppliers should plan around a fiscal 2027 outlook that shows China softness.
Updated on Nov. 5, 2026 in Healthcare
Siemens Healthineers issued a fiscal 2027 outlook projecting 4%-5% comparable revenue growth after reporting fourth-quarter results. The company also said it will change its name to Healthineers as part of a planned spin-off from Siemens, which shareholders will vote on in February 2027.
Why it matters
Weakness in China continued to weigh on the diagnostics business, which the company cited as a drag on results. For operators in medical technology supply chains and healthcare purchasing, the outlook signals how a major diagnostics supplier expects demand and margins to move through the coming fiscal year.
Fourth-quarter revenue rose 7.3% to 6.784 billion euros while adjusted EBIT fell 2.0% to 1.077 billion euros from 1.098 billion euros. Diagnostics revenue fell 4.2% on a comparable basis to 1.067 billion euros, and China, the company's second-largest market after the US, accounts for about 10% of group revenue.
The players
Siemens Healthineers
Germany-based medical technology company operating imaging, laboratory diagnostics, and advanced therapies businesses, with China as its second-largest market after the US.
Siemens
German industrial conglomerate and the parent company from which Siemens Healthineers is planning a spin-off.
The details
Siemens Healthineers, the Germany-based medical technology company, tied its outlook to continued pressure in its diagnostics unit. The company attributed the China weakness to structural changes in the market environment rather than a single event. Its fiscal 2027 guidance includes adjusted basic earnings per share of 2.20 euros to 2.40 euros, giving operators a concrete range against which to measure results in the year ahead.
Timeline
Nov 5, 2026: Company issues fiscal 2027 outlook after fourth-quarter results.
February 2027: Shareholders are due to vote on the planned spin-off from Siemens.
Market Landscape
The planned spin-off from Siemens sets the timeline for Healthineers to operate as an independent medical technology company, with the February 2027 shareholder vote as the key milestone. China's role as the second-largest market, at about 10% of group revenue, means diagnostics weakness there carries weight for the company's overall performance.
Operators in healthcare procurement and medical device distribution should factor in the 4%-5% revenue growth outlook and the 2.20 to 2.40 euro EPS range when planning supplier relationships for fiscal 2027. Companies with exposure to diagnostics sales in China should monitor whether the structural market changes persist, since the segment declined 4.2% on a comparable basis in the fourth quarter.
The takeaway
The fiscal 2027 outlook gives a measurable benchmark of 4%-5% comparable growth against which the company's performance can be tracked. Operators should note the February 2027 shareholder vote on the spin-off, since a completed separation would change the company's name and reporting structure.
What happens next
Shareholders are due to vote on the planned spin-off from Siemens in February 2027, which will determine the company's independent status and new name.
Further reading
For broader context on how medical technology suppliers are navigating pricing and demand shifts, see coverage in Healthcare.
